talampanel inn development codes gyki drug investigated treatment malignant amyotrophic lateral sclerosis may results trial als found talampanel currently development talampanel acts noncompetitive antagonist ampa receptor type ionotropic glutamate receptor central nervous showed effectiveness epilepsy clinical trials development suspended due poor pharmacokinetic profile namely short terminal halflife hours necessitated multiple doses per httpsenwikipediaorgwikitalampanel